视网膜母细胞瘤免疫治疗研究进展

Progress in immunotherapy of retinoblastoma

视网膜母细胞瘤(RB)作为一种儿童最常见的恶性肿瘤,其治疗方式一直备受关注。目前,虽然RB已成功采用一系列保守治疗方式来保留眼球和保存视功能,但由于RB可通过视神经扩散到中枢神经系统,并通过巩膜、眶骨的淋巴和血液循环进行远处转移。在这种情况下,RB的多数治疗方式的治疗效果均不佳。目前需要一种新的RB治疗方式,不仅能够更有效地抑制肿瘤生长,同时也能控制肿瘤的远处转移。免疫治疗能使正常组织的损伤最小化,更具有特异性,且可以防止随后的肿瘤复发,对于治疗RB具有很大的应用前景。本文将对RB免疫治疗最新进展进行综述。

Retinoblastoma(RB),as one of the most common malignant tumors in children,has been well concerned for its treatment.Although a series of conservative methods have been successfully preserved the eyeball and visual function in RB patients,it can spread to the central nervous system through the optic nerve,and cause distant metastases through the sclera,the lymph nodes of the orbital bone,and the blood circulation.Therefore,most of current therapeutic strategies do not yield a satisfactory efficacy on RB.A novel therapeutic strategy for RB is urgently needed to effectively control tumor growth and prevent distant metastasis.Immunotherapy is a highly specific treatment that minimizes the damage to normal tissues,and prevents subsequent recurrence,which is promising in the treatment of RB,and is being increasingly applied in clinical practices.This study aims to review the latest progress of immunotherapy for RB.